(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 54.04% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.7%.
Tg Therapeutics's revenue in 2025 is $264,790,000.On average, 2 Wall Street analysts forecast TGTX's revenue for 2025 to be $84,255,418,681, with the lowest TGTX revenue forecast at $84,046,827,133, and the highest TGTX revenue forecast at $84,464,010,228. On average, 4 Wall Street analysts forecast TGTX's revenue for 2026 to be $112,665,898,789, with the lowest TGTX revenue forecast at $100,127,056,135, and the highest TGTX revenue forecast at $120,874,131,851.
In 2027, TGTX is forecast to generate $150,658,047,201 in revenue, with the lowest revenue forecast at $127,645,573,880 and the highest revenue forecast at $162,794,806,297.